Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals (NQ: ALNY )

296.48 +4.47 (+1.53%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 447,936
Open 292.10
Bid (Size) 275.00 (1)
Ask (Size) 302.00 (1)
Prev. Close 292.01
Today's Range 291.90 - 297.50
52wk Range 141.97 - 304.39
Shares Outstanding 118,847,693
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma. 
Via Investor's Business Daily
Alnylam to Webcast Conference Call Discussing Third Quarter 2024 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire

Performance

YTD
+52.10%
+52.10%
1 Month
+9.07%
+9.07%
3 Month
+26.54%
+26.54%
6 Month
+102.97%
+102.97%
1 Year
+83.01%
+83.01%

More News

Read More
Alnylam Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Why NASDAQ:ALNY qualifies as a high growth stock.
Via Chartmill
If You Invested $100 In This Stock 15 Years Ago, You Would Have $1,300 Today
Via Benzinga
Looking Into Alnylam Pharmaceuticals's Recent Short Interest
Via Benzinga
Market Whales and Their Recent Bets on ALNY Options
Via Benzinga
$1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Alnylam Submits Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Coinbase, Nike And Moderna Are Among Top 11 Large Cap Losers Last Week (Sept 30-Oct 4): Are The Others In Your Portfolio?
Via Benzinga
Alnylam's Concedes Its Patent Infringement Case Against Moderna's COVID-19 Vaccine
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
$100 Invested In This Stock 5 Years Ago Would Be Worth $300 Today
Via Benzinga
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Webcast TTR Investor Day
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
Via Investor's Business Daily
Alnylam Stock Soars 65%: Find Out What’s Behind the Gains
Via MarketBeat
Exposures Product Safety
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 10 Years
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Alnylam Pharmaceuticals Stock Falls After Detailed Vutrisiran Data For A Condition With Stiff Heart Muscles
Via Benzinga
Alnylam Plummets, Reversing 50% Gain This Year, As Pfizer Rival Lags Expectations
Via Investor's Business Daily
Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 10 Years
Via Benzinga
The 3 Best Gene Editing Stocks to Buy in August 2024
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.